STOCK TITAN

Spero Therapeuti - SPRO STOCK NEWS

Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.

Overview of Spero Therapeutics Inc

Spero Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutic candidates to combat high unmet medical needs, especially in the treatment of multidrug-resistant (MDR) bacterial infections and rare diseases. As an innovator in the field, Spero leverages a culture of respect, action, collaboration, and transparency to foster groundbreaking approaches in antibiotic research and development. With a robust pipeline that includes both oral and intravenous treatment options, the company is focused on addressing critical gaps in current medical therapies.

Core Therapeutic Focus and Pipeline

The company’s research portfolio is centered on three primary investigational product candidates:

  • Tebipenem HBr: An investigational oral carbapenem-class antibiotic designed specifically for adults, aimed at treating MDR Gram-negative infections. This product emphasizes ease of administration by offering a potential out-patient treatment approach to infections that are traditionally managed in hospital settings.
  • SPR720: Initially developed as an oral antibiotic candidate focused on addressing rare conditions such as pulmonary non-tuberculous mycobacterial (NTM) infections. SPR720 exemplified the company’s commitment to targeting niche segments with significant unmet need, even though its development has been restructured based on emerging study data.
  • SPR206: A next-generation, intravenously administered polymyxin designed for use in hospital settings. This investigational product is being evaluated as a potential therapy against MDR Gram-negative pathogens including strains that are resistant to conventional antibiotic treatments.

Business Model and Market Position

Spero Therapeutics generates value through rigorous scientific research, strategic clinical development, and robust collaboration with industry partners. In licensing its innovative therapies, as seen with the exclusive commercialization agreement for tebipenem HBr in various territories, the company underscores its commitment to leveraging partnerships that enhance its development capabilities while maintaining focused expertise in drug innovation. This business model, centered on addressing high unmet clinical needs through advanced antibiotic therapies, sets Spero apart in the competitive biopharmaceutical landscape.

Scientific Expertise and Operational Excellence

At the heart of Spero’s operations is a team composed of leaders in microbiology and pharmaceutical sciences, driving forward its research initiatives with precision and scientific rigor. The company’s operational framework is built upon collaborative research, evidence-based development, and transparent clinical reporting—elements that underscore its dedication to enhancing patient outcomes while addressing the global threat of antibiotic resistance.

Competitive Landscape and Differentiation

In a market increasingly focused on solutions to antibiotic resistance, Spero Therapeutics differentiates itself through its targeted approach toward MDR infections and rare diseases. Its pipeline illustrates a dual strategy: offering an oral treatment option with tebipenem HBr to potentially reduce hospitalization needs, as well as advanced intravenous options like SPR206 for acute clinical settings. This dual pathway not only positions Spero competitively against traditional antibiotic developers but also highlights its nuanced understanding of clinical needs across diverse patient populations.

Clinical Rigor and Transparent Communication

The company’s approach to development is underscored by robust clinical studies and transparent communication of its findings, ensuring that all stakeholders—from research scientists to healthcare professionals—can trust in its methodological rigor. Spero consistently emphasizes solid data from its trials, incorporating iterative feedback to refine its candidate profiles, and maintains a culture that is both innovative and critically evaluative of its own methods.

Investor and Industry Relevance

For investors and industry analysts, Spero Therapeutics represents a focused example of how advanced scientific methodologies and a clear clinical vision can converge to tackle some of the most challenging infections of our time. Each product candidate is supported by a series of strategic decisions, aligning the company’s research interests with practical healthcare needs. The company’s restructuring efforts and resource allocation further illustrate its strategic management practices, aimed at optimizing its research focus and preserving long-term operational sustainability.

In summary, Spero Therapeutics Inc is not only engaged in the pursuit of innovative antibiotic treatments but also exemplifies a commitment to scientific excellence and operational transparency. Its strategic focus on addressing MDR bacterial infections and rare diseases through both oral and IV candidates makes it a notable entity within the biopharmaceutical industry, poised to contribute critical solutions in the ongoing battle against antibiotic resistance.

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) reported its Q1 2021 financial results, showing a net loss of $19.4 million, improved from $23.3 million a year earlier. Total revenues surged to $7.3 million, up from $1.7 million, mainly due to a BARDA grant for tebipenem HBr. The company remains on track for an NDA submission of tebipenem HBr in H2 2021 after a successful pre-NDA meeting with the FDA. However, the Phase 2a trial of SPR720 is on hold due to non-human primate mortalities, leading to trial discontinuation while further data is analyzed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced the grant of non-qualified stock options to new employees, totaling 28,600 shares, as part of its 2019 Inducement Equity Incentive Plan. The stock options, awarded on April 30, 2021, have an exercise price of $13.76, equivalent to the closing price on that day. Each option will vest over four years, with 25% vesting after the first year. Spero focuses on developing treatments for multi-drug resistant infections and rare diseases, with its lead product candidate, tebipenem HBr, aimed at treating complicated urinary tract infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced a conference call on May 6, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a business update.

The company focuses on developing novel treatments for multi-drug-resistant infections and rare diseases, with its lead candidate, tebipenem HBr, showing positive Phase 3 trial results for complicated urinary tract infections. Spero is also developing SPR720 for orphan pulmonary diseases and SPR206 targeting MDR Gram-negative infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
Rhea-AI Summary

Spero Therapeutics announced on March 31, 2021, the grant of non-qualified stock options to purchase 22,050 shares of common stock as part of its 2019 Inducement Equity Incentive Plan. These options were awarded to three new employees to incentivize their employment with the company, complying with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $14.72 per share, equal to the stock's closing price on the same day. The options vest over four years, contingent on the employees' continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) reported its fourth quarter and full-year 2020 financial results, highlighting significant progress in its drug development programs amidst COVID-19 challenges. The company plans to submit a New Drug Application (NDA) for tebipenem HBr in the second half of 2021 after successful Phase 3 trial results. In 2020, Spero faced a net loss of $78.8 million on $9.3 million in revenue, down from $18.1 million in 2019. Notably, expenses in R&D decreased, but G&A expenses rose due to increased staffing. Spero has $126.9 million in cash reserves, expected to sustain operations into Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.58%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on March 11, 2021, at 4:30 p.m. EST to discuss its fourth quarter and full-year 2020 financial results as well as updates on its business and pipeline. The call will be accessible via phone or an audio webcast on the company’s website. Spero focuses on developing novel treatments for multi-drug-resistant bacterial infections and rare diseases, with key products including tebipenem HBr, a potential first oral carbapenem antibiotic for complicated urinary tract infections, and SPR720 for rare pulmonary diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that its CEO, Ankit Mahadevia, M.D., will present at two upcoming investor conferences in March 2021. The events include the Cowen 41st Annual Healthcare Conference on March 1, and the Oppenheimer 31st Annual Healthcare Conference on March 16. The presentations will focus on Spero's development of treatments for multi-drug resistant bacterial infections and rare diseases, including its lead candidate, tebipenem HBr, aimed at treating complicated urinary tract infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
conferences
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced a clinical hold on its Phase 2a trial of SPR720, an oral antimicrobial agent for nontuberculous mycobacterial pulmonary disease. This action follows a pause in dosing due to concerns raised by an ongoing animal toxicology study, which observed mortalities in non-human primates. No serious adverse events have been reported in human trials, and the FDA is in discussions with Spero to evaluate findings. SPR720 has the potential to offer a new treatment option for patients with this rare disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced on January 29, 2021, that its Board of Directors granted stock option awards totaling 74,300 shares to six new employees. This grant, made under the 2019 Inducement Equity Incentive Plan, complies with Nasdaq Listing Rule 5635(c)(4). The options, priced at $18.11 per share, will vest over four years. Spero is focused on developing treatments for multi-drug resistant infections and rare diseases, with key products including tebipenem HBr for complicated urinary tract infections and SPR720 for non-tuberculous mycobacterial infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the issuance of U.S. Patent No. 10,889,587 for its oral carbapenem, tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). This patent protects its formulation and expires in February 2038. The company previously reported positive results from its Phase 3 clinical trial of tebipenem HBr in September 2020. With Qualified Infectious Disease Product status and fast track designation from the FDA, Spero plans to submit a New Drug Application in the second half of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none

FAQ

What is the current stock price of Spero Therapeuti (SPRO)?

The current stock price of Spero Therapeuti (SPRO) is $0.694 as of April 1, 2025.

What is the market cap of Spero Therapeuti (SPRO)?

The market cap of Spero Therapeuti (SPRO) is approximately 37.6M.

What is the core focus of Spero Therapeutics?

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for multidrug-resistant bacterial infections and rare diseases.

What product candidates are in Spero Therapeutics' pipeline?

The company is focused on developing tebipenem HBr, an oral carbapenem antibiotic, SPR720 for pulmonary non-tuberculous mycobacterial infections, and SPR206, a next-generation IV polymyxin.

What is tebipenem HBr designed to treat?

Tebipenem HBr is an investigational oral antibiotic developed to treat MDR Gram-negative infections, offering a potential outpatient treatment option.

How does SPR206 differentiate itself in the market?

SPR206 is a next-generation, intravenously administered polymyxin designed to combat MDR Gram-negative pathogens, particularly in hospital settings where severe infections are managed.

Why is addressing multidrug-resistant infections important for Spero Therapeutics?

By targeting MDR bacterial infections, Spero Therapeutics addresses a critical healthcare challenge, contributing innovative solutions to a field with limited effective treatment options.

How does Spero demonstrate its expertise in drug development?

Spero employs a team of experienced scientists and clinicians, utilizes rigorous clinical trial methodologies, and maintains transparency in its research, showcasing its commitment to high scientific standards.

What impact does Spero Therapeutics aim to have on public health?

The company aims to reduce the burden of MDR infections by developing innovative therapeutic options that improve treatment outcomes, reduce hospitalizations, and address previously unmet clinical needs.

How does Spero maintain transparency and credibility in its research?

Spero is committed to transparent communication of its clinical data and strategic decisions, ensuring that its research findings and operational practices are clearly documented and accessible to stakeholders.
Spero Therapeuti

Nasdaq:SPRO

SPRO Rankings

SPRO Stock Data

37.62M
41.52M
24.47%
24.89%
0.78%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE